MacroGenics, Inc.
(NASDAQ : MGNX)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Bitcoin & Crypto Movers
Receive our Bitcoin / Cryptocurrency Reports, Free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
ARRYArray BioPharma Inc.
0.16%46.508.1%$739.78m
AMGNAmgen Inc.
0.32%176.691.3%$505.23m
CELGCelgene Corporation
0.05%91.811.3%$444.44m
GILDGilead Sciences, Inc.
-1.51%67.040.9%$405.24m
BIIBBiogen Inc.
-0.33%232.851.3%$386.39m
ILMNIllumina, Inc.
0.05%302.443.5%$335.95m
REGNRegeneron Pharmaceuticals, Inc.
-0.15%297.752.6%$277.74m
SRPTSarepta Therapeutics, Inc.
-2.73%152.6314.7%$203.17m
ALXNAlexion Pharmaceuticals, Inc.
0.70%123.902.0%$199.53m
VRTXVertex Pharmaceuticals Incorporated
0.22%176.761.9%$187.90m
EXASExact Sciences Corporation
-0.44%115.6824.1%$139.87m
AAgilent Technologies, Inc.
-1.01%69.841.6%$133.90m
INCYIncyte Corporation
-1.38%80.272.5%$114.50m
BLUEBluebird Bio, Inc.
-1.67%133.4814.3%$97.55m
BMRNBioMarin Pharmaceutical Inc.
-1.81%82.474.3%$87.74m

Company Profile

MacroGenics, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering and developing antibody-based therapeutics designed to modulate the human immune response for the treatment of cancer. 2. Its product pipeline includes Margetuximab, Flotetuzumab, Enoblituzumab, MGA012, MGD013, MGD019, MGD009, MGC018, and MGD007 for oncology; and MGD014 for infectious diseases. The company was founded by Scott E. Koenig, Jeffrey V. Ravetch, LeRoy E. Hood, Ruedi Aebersold, and Alan Aderem on August 14, 2000 and is headquartered in Rockville, MD.